Crinetics Pharmaceuticals, Inc.CRNXNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

defenseworld.net

Crinetics Pharmaceuticals Highlights Early PALSONIFY Sales, EU Milestone, and GPCR Pipeline at TD Cowen Conf.

Executives from Crinetics Pharmaceuticals (NASDAQ: CRNX) used an investor discussion at TD Cowen's 46th Annual Healthcare Conference to highlight early U.S. commercial progress for its newly launched acromegaly drug, outline upcoming regulatory and clinical milestones, and describe how its pipeline is built around novel small-molecule therapies targeting G protein-coupled receptors (GPCRs). PALSONIFY launch: early demand, reimbursement

defenseworld.net

Intech Investment Management LLC Has $926,000 Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX

Intech Investment Management LLC lessened its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) by 47.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,225 shares of the company's stock after selling 20,408 shares during the quarter. Intech Investment Management LLC's

seekingalpha.com

Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript

zacks.com

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to a loss of $0.88 per share a year ago.

globenewswire.com

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December

defenseworld.net

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of “Moderate Buy” by Analysts

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and eleven have issued a buy rating on the company. The average 1-year price objective

globenewswire.com

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46 th Annual Health Care Conference, Boston, MA Fireside chat on Wednesday, March 4, 2026 at 1:50 p.m. Eastern Time Webcast link HERE Management will be available for 1x1 meetings with investors on Wednesday, March 4, 2026 Leerink Annual Global Healthcare Conference, Miami, FL Management will be available for 1x1 meetings with investors on Wednesday, March 11, 2026 The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the Crinetics' website at www.crinetics.com/events.

defenseworld.net

Critical Review: Xenetic Biosciences (NASDAQ:XBIO) & Crinetics Pharmaceuticals (NASDAQ:CRNX)

Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends. Profitability This table compares Crinetics Pharmaceuticals and Xenetic

globenewswire.com

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

globenewswire.com

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

SAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH) in children and adolescents. “BALANCE-CAH is designed to evaluate atumelnant for the treatment of CAH in pediatric age patients – for whom the lifelong burden of this disease begins early,” said Dr. Alan Krasner, M.D.

seekingalpha.com

Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

globenewswire.com

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,575 shares of its common stock and granted an aggregate of 25,525 restricted stock unit (“RSU”) awards to 10 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

globenewswire.com

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 7,620,000 shares of its common stock at a price to the public of $45.95 per share. All of the shares to be sold in the offering are to be sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $350 million. In addition, Crinetics has granted the underwriters a 30-day option to purchase up to an additional 1,143,000 shares of common stock. The offering is expected to close on or about January 8, 2026, subject to the satisfaction of customary closing conditions.

defenseworld.net

Crinetics Pharmaceuticals touts $5M Palsonify Q4 launch, posts strong atumelnant phase 2 CAH data

Crinetics Pharmaceuticals (NASDAQ: CRNX) provided a corporate update highlighting early commercial progress for Palsonify in acromegaly and new phase 2 data for atumelnant in congenital adrenal hyperplasia (CAH), along with details on the ongoing phase 3 program. Palsonify launch: early uptake and fourth-quarter revenue Chief Executive Officer Scott Struthers said the company is "excited" with the

globenewswire.com

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, $350.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock. All of the shares to be sold in the proposed offering are to be sold by Crinetics. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

seekingalpha.com

Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia Transcript

globenewswire.com

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (80 mg) Achieved a 67% Mean Reduction in Androstenedione Levels While Simultaneously Enabling 88% of Participants Completing 12 Weeks of Treatment to Successfully Reduce Glucocorticoid Dose to Physiologic Replacement Levels Atumelnant's Favorable Benefit/Risk Profile Was Maintained in Cohort 4 and Open-Label Extension of Phase 2 CAH Study With No Hepatic Transaminase Adverse Events Management to Host Investor Conference Call Today at 8:30 AM ET SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced PALSONIFY U.S. unaudited and preliminary net product revenue of over $5 million for fourth-quarter 2025. Crinetics also announced positive topline results from the fourth cohort of its Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing's syndrome.

globenewswire.com

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY™ (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia.

defenseworld.net

Squarepoint Ops LLC Has $1.21 Million Stake in Crinetics Pharmaceuticals, Inc. $CRNX

Squarepoint Ops LLC lessened its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) by 69.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,070 shares of the company's stock after selling 97,422 shares during the period. Squarepoint

globenewswire.com

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 13, 2026 at 9:45 a.m. Pacific Time.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance